QuickSwitch kits for Class II MHC Tetramers for analysis of CD4+ T cells have been created to meet the needs of scientists looking for better understanding of the CD4+ T cell responses.
The clinical resupply services will be delivered under AdAlta’s contract development and manufacturing Master Services Agreement with KBI Biopharma that was announced on 5 June 2018.
Selexis and KBI announced today that they have signed service agreements with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting canc...
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
